Plans to Implement Fee-for-Value Models in Oncology

Partner | Oncology Network Providers | <b>RCCA</b>

Terrill Jordan, president and CEO of Regional Cancer Care Associates, discusses RCCA’s efforts to further the fee-for-value model in oncology and make drugs more readily available to patients with cancer.

Terrill Jordan, president and CEO of Regional Cancer Care Associates (RCCA), discusses RCCA’s efforts to further the fee-for-value model in oncology and make drugs more readily available to patients with cancer.

RCCA is working with payers to make sure patients get access to vital medicines and is working with new technologies to make better drug selections for patients, says Jordan. Efforts are being made to ensure that a drug is not being used if a patient is not responding to that therapy. Much work needs to be done in terms of working with technology. RCCA has an affiliation with COTA, which is aggregating real-world data on patient outcomes.

That technology is being used to identify the patients who can benefit from individualized therapy. When RCCA aligns its goals with the right technology for that purpose, prior authorization for a drug may be unnecessary because the payers will already know that the drug will be effective. That way, drugs can be priced appropriately, says Jordan.